Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Syngene International Limited is a leading integrated research, development, and manufacturing organization serving sectors like pharmaceuticals, biotechnology, nutrition, and chemicals. Its two main segments, Research Services and Contract Development Manufacturing Services (CDMO), offer a wide range of capabilities across large and small molecules.
The company’s strategic partnerships, particularly its extended relationship with Bristol Myers Squibb, underscore its robust collaborative framework, supporting its scientific and operational expansion until 2035.
Significant challenges emerged with a notable decline due to the impact from a single large molecule biologics product, affecting short-term financial performance and leading to revised guidance of a 3–5% decline in annual revenue.
Despite current setbacks, underlying segments like research services are showing growth, driven by increasing capacity utilization in both small and large molecules, along with a diversified business model and strong client relationships.
Strategic investments in specialized facilities for high-potency compounds and advancements in biologics assay and fill-finish capabilities highlight Syngene's commitment to fortifying its R&D infrastructure and service diversification.
Healthcare Services
Healthcare Research, Analytics & Technology
17,409 Cr
Moderate Risk
55.0
56.4
1.4
3.7
754.00
380.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
404.60 | 17,409 Cr | 49.44 | 3.68 | 0.29 | 9.89 | 11.96 | 5.38 | ||
496.00 | 11,934 Cr | 27.18 | 4.16 | 0.40 | 15.56 | 19.82 | 12.28 | ||
167.10 | 5,728 Cr | -20.85 | 7.47 | 0.00 | -75.33 | -75.33 | -81.41 | ||
408.05 | 2,138 Cr | 34.83 | 6.24 | 0.21 | 14.59 | 19.04 | 13.94 | ||
46.04 | 641 Cr | 398.23 | 24.85 | 0.00 | 15.55 | 21.32 | 4.57 | ||
64.02 | 158 Cr | -51.37 | 2.48 | 0.00 | -9.29 | -5.26 | -2.47 | ||
57.69 | 144 Cr | -12.50 | 0.32 | 0.00 | -2.81 | 0.93 | -2.96 | ||
| Median: 7 Co. | — | 167.10 | 2,138 Cr | 27.18 | 4.16 | 0.00 | 9.89 | 11.96 | 4.57 |
Syngene International Ltd (SYNGENE) is currently trading at 467.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Syngene International Limited is a leading integrated research, development, and manufacturing organization serving sectors like pharmaceuticals, biotechnology, nutrition, and chemicals. Its two main segments, Research Services and Contract Development Manufacturing Services (CDMO), offer a wide range of capabilities across large and small molecules. The company’s strategic partnerships, particularly its extended relationship with Bristol Myers Squibb, underscore its robust collaborative framework, supporting its scientific and operational expansion until 2035. Significant challenges emerged with a notable decline due to the impact from a single large molecule biologics product, affecting short-term financial performance and leading to revised guidance of a 3–5% decline in annual revenue. Despite current setbacks, underlying segments like research services are showing growth, driven by increasing capacity utilization in both small and large molecules, along with a diversified business model and strong client relationships. Strategic investments in specialized facilities for high-potency compounds and advancements in biologics assay and fill-finish capabilities highlight Syngene's commitment to fortifying its R&D infrastructure and service diversification.
Over the past 52 weeks, Syngene International Ltd has traded between a low of ₹380.00 and a high of ₹754.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Syngene International Ltd has a market capitalization of approximately 17,409.00. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Syngene International Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 54.97 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 17,409.00 Cr, Syngene International Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Syngene International Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Syngene International Ltd is 54.97. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The provided snapshot states Syngene International (SYNGENE) was at ₹433.40 on 29 April 2026.
Syngene reported FY26 consolidated revenue of ₹3,738.7 crore and profit for the year of ₹316.7 crore for the year ended March 31, 2026.
FY26 revenue from operations rose 3% to Rs 3,739 crore, while profit after tax (before exceptional items) was Rs 380 crore and reported profit after exceptional items was Rs 317 crore.
Revenue from operations rose to ₹3,739 crore in FY26 from ₹3,642 crore. PAT before exceptional items was ₹380 crore, and reported PAT after exceptional items was ₹317 crore.
Bearish
6
Neutral
3
Bullish
5
Bearish
14
Neutral
3
Bullish
29
Bearish
8
Neutral
0
Bullish
24
Investor Presentation
Syngene released its Q4 & FY26 investor presentation: FY26 revenue Rs 3,739 Cr (+3% YoY), PAT Rs 380 Cr (-20% YoY) with margin compression; ADC capability started and senior management changes announced (new MD & CEO Siddharth Mittal).
Results & Dividend
Board approved audited standalone and consolidated financial results for FY2025‑26, recommended a final dividend of Re.1.25/share (record date June 26, 2026), approved AGM on July 29, 2026 and appointment of S.R. Batliboi as statutory auditors (subject to shareholder approval).
Audited Results & Dividend
Board approved audited standalone and consolidated results for quarter/year ended Mar 31, 2026; recommended final dividend Re.1.25/share (record date Jun 26, 2026); appointed S.R. Batliboi & Associates LLP as statutory auditors (subject to shareholder approval); AGM on Jul 29, 2026.
Results & Dividend
Board approved audited standalone & consolidated results for FY2025-26, recommended final dividend of Re.1.25 per equity share (record date June 26, 2026), appointed S.R. Batliboi as statutory auditors (subject to approval) and fixed AGM on July 29, 2026.
Board meeting outcome
Board approved audited consolidated and standalone Ind-AS financial results for quarter and year ended Mar 31, 2026; recommended final dividend of Re.1.25/share (record date Jun 26, 2026); appointed S.R. Batliboi as statutory auditors (subject to shareholder approval); AGM set for Jul 29, 2026.
